As you start to learn about stem cells, one of the most common questions to have is, “What types of stem cells exist?” There is not an agreed-upon number of stem cell types, because one can classify stem cells either by differentiation potential (what they can turn into) or by origin (from where they are sourced). This post is dedicated to explaining the five types of stem cells, based on differentiation potential. [Read more…]
The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy
What do we know of the safety and efficacy of stem cell therapeutics? Over 50 years have passed since the discovery of hematopoietic stem cells (bone marrow transplantation to cure diseases such as leukemia), over 20 years since the discovery of human embryonic stem cells (hESC), and 15 years since the discovery of induced pluripotent stem cells (iPS cells). There are now thousands of stem cell trials underway in clinics worldwide.
Despite this experience, what do we actually know about the safety and efficacy of stem cell therapeutics? [Read more…]
Implant Therapeutics To Engineer iPSC-MSC Cells Containing panCELLa’s Technologies
TORONTO, Jan. 8, 2021– panCELLa’s intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics.
Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering iPSC-MSC cells containing panCELLa’s FailSafe™ and induced Allogeneic Cell Tolerance (iACT Stealth Cell™) technologies. These iPSC MSC cells are hypo-immunogenic and are an ideal choice for bone, cartilage and tendon replacement strategies combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles. [Read more…]
Burgeoning Number of iPSC Therapies To Be Tested in Clinical Trials
Therapeutic applications of induced pluripotent stem cells (iPSCs) have surged in recent years. Since the creation of human iPSCs in 2007, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2014. From 2014 to present, additional trials and physician-led studies employing human iPSC-derived cell types have been initiated across multiple geographies worldwide. [Read more…]
Evotec Achieves Milestone within iPSC-Based Neuroscience Partnership with BMS
Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry.
HAMBURG, GERMANY / January 5, 2021 — Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced that the Company has received a US $6 million payment from Bristol Myers Squibb Company (NYSE: BMY) within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio. [Read more…]
